Sinovac Biotech Ltd. (SVA) — Institutional Investor Activity (Q2 2026)

SVA ranks #7554 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

29 institutions disclose a position in SVA, but none treat it as a major bet — even Vivo Capital, LLC, its most concentrated holder, allocates just 3.5% of its own portfolio to it.

Wells Fargo & Company/mn has trimmed its SVA position for two straight quarters, cutting it by $79.6K while still holding $29.6K.

SVA reported a net loss of $198.8M in its latest fiscal year.

• Not yet profitable — net loss of $198.8M in the latest fiscal year
• Net income declined year over year, from $40.7M to -$198.8M
• Operating cash flow was negative, using $512.2M in cash
• Current ratio of 4.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.48x equity — within a conventional range